First AD

Second AD

Challenges With Current Treatment Options for CSU

Video content above is prompted by the following:

What are the challenges associated with the use of biologics for CSU?

We previously discussed the role that BTK plays in mediating mast cell degranulation. Why does this make BTK an ideal target for CSU treatment?


Peer Exchange: Evolving Perspectives and Treatment Strategies in Chronic Spontaneous Urticaria 

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Peer Exchange

Biologics for chronic spontaneous urticaria (CSU) present challenges such as high costs, potential side effects, and the need for precise patient selection to ensure efficacy. The role of Bruton's tyrosine kinase (BTK) in mast cell degranulation makes it an attractive target for CSU treatment, as inhibiting BTK can potentially reduce the release of histamines and other mediators involved in the inflammatory response. This targeted approach may offer a more effective and specific treatment option for patients with CSU, addressing the underlying pathophysiology of the condition.

Panelists discuss the challenges associated with using biologics for chronic spontaneous urticaria (CSU), including issues related to accessibility and cost, while also explaining why Burton tyrosine kinase (BTK) is considered an ideal target for CSU treatment due to its role in mediating mast cell degranulation.